Postdoc Fellow, Discovering Novel Genetic and Epigenetic Regulations
- City of Hope
- Location: Monrovia, CA
- Job Number: 7067402 (Ref #: 10006395rxv_104_1)
- Posting Date: Jul 2, 2020
- Application Deadline: Open Until Filled
Job DescriptionAbout City of Hope
City of Hope, an innovative biomedical research, treatment and educational institution with over 6000 employees, is dedicated to the prevention and cure of cancer and other life-threatening diseases and guided by a compassionate, patient-centered philosophy.
Founded in 1913 and headquartered in Duarte, California, City of Hope is a remarkable non-profit institution, where compassion and advanced care go hand-in-hand with excellence in clinical and scientific research. City of Hope is a National Cancer Institute designated Comprehensive Cancer Center and a founding member of the National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers that develops and institutes standards of care for cancer treatment.
We have an immediate need for a Postdoctoral Fellow in the Chen Laboratory, in the Department of Systems Biology, at Beckman Research Institute of City of Hope, ( https://www.cityofhope.org/faculty/jianjun-chen ). Our group is interested in discovering novel genetic and epigenetic regulations and deciphering their underlying molecular mechanisms in normal developmental processes (e.g., hematopoiesis) and tumorigenesis (e.g., leukemogenesis). We cover research areas with relevance to Hematology, Immunology, and Cancer Biology, with an emphasis on RNA epigenetics (mainly focusing on the N6 methyladenosine (m6A) modification) and DNA epigenetics (mainly focusing on the TET1/2/3- mediated DNA demethylation) associated basic and translational research. Our research involves experiments with primary human cancer cells, cancer and stem cell transplantation models, mouse genetics, classic molecular, biochemistry and cell biology, functional genomics, signal transduction, and large-scale data analysis and computational biology.
Key Responsibilities include:
- Flow cytometry,
- Mass spectrometry/quantitative phospho-profiling,
- CyTOF, mouse genetics, bone marrow transplantation assays, retroviral gene delivery,
- Whole exome sequencing and RNA-seq-analysis of clonal evolution of cancer, m6A/5hmC dot blots, m6A-seq, 5hmC-seq, ChIP-seq, RIP-seq, PAR-CLIP-seq, pre-clinical drug testing in xenotransplantation models.
Basic education, experience and skills required for consideration:
- The candidates for the Postdoctoral scientist position should have a Ph.D. and/or M.D. degree(s), and a solid background in biochemistry, mouse model studies, hematology, epigenetics, immunology, pathology, and/or stem cell research.
- The candidates should not have more than three years of postdoc training experience.
- The candidates should be highly motivated individuals with the ability to work in a team environment and with good oral and written communication skills in English.
Your application, including CV, brief motivation statement, and contact information of three scientific mentors (references), should be saved as a single PDF. The PDF file can be sent to Dr. Jianjun Chen ( email@example.com ) directly.
Examples of recent work:
- Jiang X, Huang H, Li Z (…) & Chen J. Blockade of miR-150 maturation by MLLfusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 22: 524-535.(2012)
- Li Z, Herold T, He C (…) & Chen J. Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study of 1,324 Patients. Journal of Clinical Oncology. 31(9):1172-81. (2013)
- Jiang X, Hu C, Arnovitz S (…) & Chen J. miR-22 has a potent anti-tumor role with therapeutic potential in acute myeloid leukemia. Nature Communications. 7:11452. (2016)
- Li Z, Weng H, Su R, (…) & Chen J. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. Cancer Cell. 31(1):127-141.(2017)
- Jiang X, Hu C, Ferchen K (…) & Chen J. Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nature Communications. 8:2099.(2017)
- Su R, Dong L, Li C (…) & Chen J. R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling. Cell. 172(1-2):90-105. (2018)
- Weng H, Huang H, Wu H (…) & Chen J. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. Cell Stem Cell. 22(2):191-205. (2018)
- Huang H, Weng H, Sun W, (…) Chen J. Recognition of RNA N6-methyadenosine by IGF2BP proteins Enhances mRNA Stability and Translation. Nature Cell Biology. 20(3):285-295. (2018)
City of Hope is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, religion, color, national origin, sex, sexual orientation, gender identity, age, status as a protected veteran, or status as a qualified individual with disability.
City of Hope is a community of people characterized by our diversity of thought, background and approach, but tied together by our commitment to care for and cure those with cancer and other life-threatening diseases. The innovation that our diversity produces in the areas of research, treatment, philanthropy and education has made us national leaders in this fight. Our unique and diverse workforce provides us the ability to understand our patients' needs, deliver compassionate care and continue the quest for a cure for life-threatening diseases. At City of Hope, diversity and inclusion is a core value at the heart of our mission. We strive to create an inclusive workplace environment that engages all of our employees and provides them with opportunities to develop and grow, both personally and professionally. Each day brings an opportunity to strengthen our work, leverage our different perspectives and improve our patients’ experiences by learning from others. Diversity and inclusion is about much more than policies and campaigns. It is an integral part of who we are as an institution, how we operate and how we see our future.